secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001104659-26-003121
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves ZYCUBO for Menkes disease; Cyprium gets PRV, up to $129M milestones
--------------------------------------------------------------------------------

- FDA approved ZYCUBO (copper histidinate) as first and only U.S. treatment for Menkes disease in pediatric patients.
- Rare Pediatric Disease PRV issued at approval and will be transferred to Cyprium, a majority-owned Fortress subsidiary.
- Cyprium eligible for tiered royalties on net sales and up to $129M in aggregate development and sales milestones from Sentynl.
- Early ZYCUBO treatment showed median overall survival of 177.1 months vs 17.6 months in external control (≈80% risk reduction).
- Fortress notes three FDA approvals in 15 months (Emrosi, UNLOXCYT, ZYCUBO) and recent $28M upfront from Checkpoint sale to Sun Pharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926003121/0001104659-26-003121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926003121/fbio-20260113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-003121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer